Micromet received a $10-million milestone payment from Serono having completed two Phase II trials with its cancer drug. Adecatumumab (MT201) was evaluated as a single agent for the treatment of metastatic breast cancer and prostate cancer. It is a human Mab targeting tumor cells overexpressing the epithelial cell adhesion molecule.
Micromet and Serono reported final data for the two Phase II in October. The compound originated at Micromet and is being developed in a collaboration between the companies.